Biomea Fusion announced that the first patient has been dosed in COVALENT-103, the company’s Phase I trial of BMF-500, an investigational covalent FLT3 inhibitor developed using the proprietary FUSION System, in adult patients with relapsed or refractory acute leukemia. “Today, we have taken another important step to bring novel covalent drug candidates into the clinic by exploring the potential of BMF-500, an investigational covalent FLT3 inhibitor, in treating adult patients with relapsed or refractory acute leukemia. BMF-500 is designed to be a potent molecule and is the second covalent inhibitor we have developed in-house, demonstrating the potential of the FUSIONTM platform and our team in bringing novel assets to the clinic. Beyond single agent studies of BMF-500 we are planning combination studies with various approved therapies and therapy candidates, including BMF-219, to explore the potential of this powerful dual-mechanistic approach to provide deeper and more durable treatment responses,” said Thomas Butler, Biomea’s CEO and Chairman of the Board.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMEA:
- Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
- JPMorgan biotech analysts hold an analyst/industry conference call
- Biomea Fusion announces FDA clearance of IND application for BMF-219
- Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
- Biomea Fusion announces FDA, Health Canada clearance of COVALENT-111 study